Impact on the Estimated Prohormone Convertase Enzyme Activity (PC1/3 and 2) in Japanese Type 2 Diabetes Treated with Sitagliptin

Impact on the Estimated Prohormone Convertase Enzyme Activity (PC1/3 and 2) in Japanese Type 2 Diabetes Treated with Sitagliptin - Impact on the Proinsulin Processing in Japanese Type 2 Diabetes Treated with Sitagliptin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013212

Enrollment

Registered

2014-02-21

Start date

2011-11-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

25 or 50mg sitagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: over than HbA1c 6.5% lower than FPG 270mg

Exclusion criteria

Exclusion criteria: liver dysfunction renal dysfunction

Design outcomes

Primary

Measure	Time frame
Prohormone Convertase Enzyme Activity (PC1/3 and 2)	—

Countries

Japan

Contacts

Public ContactHidenori Katsuta

Kyorin University School of Medicine Third Department of Internal Medicine, Division of Diabetes, Endocrinology and Metabolism

hkatsuta@ks.kyorin-u.ac.jp0422-47-5511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026